Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6123555 | 0.75 | CA2 (0.46) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL13237399 | 0.75 | CA1 (0.35) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL20993532 | 0.75 | CA1 (0.33) | — | |
| SCHEMBL21789213 | 0.75 | — | — | |
| SCHEMBL21540663 | 0.73 | — | — | |
| SCHEMBL10486710 | 0.72 | MAPT (0.34) | MAPTSMN1; SMN2KDM4EMEN1NPC1 | |
| SCHEMBL246883 | 0.72 | — | — | |
| SCHEMBL239787 | 0.72 | PTPN11 (0.30) | — | |
| SCHEMBL17147518 | 0.71 | PTPN11 (0.32) | — | |
| SCHEMBL17147397 | 0.71 | CA1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59186951-A | — | — | None | — | — | JP | disclosed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4230618-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-5919829-A | Gastrin and cck receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5795907-A | Gastin and CCK receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-08-18 | — | — | US | disclosed |
| EP-0720601-A1 | GASTRIN AND CCK RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995004720-A2 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 1995-02-16 | — | — | WO | disclosed |
| US-5318969-A | Hypotensive, vasodilating action and muscle relaxants | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-06-07 | — | — | US | disclosed |
| EP-0339562-B1 | BENZOPYRAN COMPOUND AND ITS PHARMACEUTICAL USE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-5143936-A | Benzopyran compound and its pharmaceutical use | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| US-5021432-A | Hypotensive agents | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0339562-A1 | Benzopyran compound and its pharmaceutical use | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-11-02 | — | — | EP | disclosed |
| JP-S59186951-A | PRODUCTION OF DI-TERT-BUTYL HYPONITRITE | WAKO PURE CHEM IND LTD | 1984-10-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | MAPT 4491/4885SMN1; SMN2 3485/4885KDM4E 3553/4885 |
| US-20230303497-A1 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | SCN8A, SCN9A, SCN10A | MAPT 1923/4885SMN1; SMN2 119/4885KDM4E 1134/4885 |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | MAPT 2250/4885SMN1; SMN2 1156/4885KDM4E 4670/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | MAPT 2544/4885SMN1; SMN2 1482/4885KDM4E 3970/4885 |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | GPR55, GPR65, GPR4 | MAPT 1267/4885SMN1; SMN2 2603/4885KDM4E 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.